The dependence of prostate postimplant dosimetric quality on CT volume determination

International Journal of Radiation Oncology Biology Physics

Volumn 44, Issue 5, 1999, Pages 1111-1117

  Merrick, Gregory S ^a,b   Butler, Wayne M ^a   Dorsey, Anthony T ^a   Lief, Jonathan H ^c  

^a WHEELING HOSPITAL   (United States)

^b GEORGE WASHINGTON UNIVERSITY MEDICAL CENTER   (United States)

^c WHEELING JESUIT UNIVERSITY   (United States)

Author keywords

CT volume; Dosimetry; Prostate brachytherapy; Quality

Indexed keywords

IODINE 125;

ARTICLE; BRACHYTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DOSIMETRY; HUMAN; IMPLANT; INTERSTITIAL RADIATION; MALE; POSTOPERATIVE CARE; PRIORITY JOURNAL; PROSTATE CARCINOMA; RADIATION DOSE; TREATMENT PLANNING;

BRACHYTHERAPY; HUMANS; IODINE RADIOISOTOPES; MALE; PROSTATIC NEOPLASMS; RADIOPHARMACEUTICALS; RADIOTHERAPY DOSAGE; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; TOMOGRAPHY, X-RAY COMPUTED; ULTRASONOGRAPHY, INTERVENTIONAL;

EID: 0032783902     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(99)00137-6     Document Type: Article

References (33)

1. Blasko J.C., Wallner K., Grimm P.D., Ragde H. Prostate specific antigen based disease control following ultrasound guided iodine-125 implantation for stage T1/T2 prostatic carcinoma. J Urol. 154:1995;1096-1099.
2. Wallner K., Roy J., Zelefsky M., Fuks Z., Harrison L. Short term freedom from disease progression after I-125 prostate implantation. Int J Radiat Oncol Biol Phys. 30:1994;405-409.
3. Wallner K., Roy J., Harrison L. Tumor control and morbidity following transperineal I-125 implantation for stage T1/T2 prostatic carcinoma. J Clin Oncol. 14:1996;449-453.
4. Dattoli M., Wallner K., Sorace R., Koval J., Cash J., Acosta R., Brown C., Etheridge J., Binder M., Brunelle R., Kirwan N., Sanches S., Stein D., Wasserman S. Pd-103 brachytherapy and external beam radiation therapy for clinically localized high risk prostatic carcinoma. Int J Radiat Oncol Biol Phys. 35:1996;875-879.
5. Ragde H., Blasko J.C., Grimm P.D., Kenny G.M., Sylvester J.E., Hoak D.C., Landin K., Cavanagh W. Interstitial I-125 radiation without adjuvant therapy in the treatment of clinically localized prostate cancer. Cancer. 80:1997;442-453.
6. Dattoli M.J., Wallner K.E., Cash J.C., Ross R.E., Koval J.M., Sorace R.A. Pd-103 brachytherapy for clinical T1/T2 prostate carcinomas. Int J Radiat Oncol Biol Phys. 39:1997;221.
7. Ragde H., Blasko J.C., Grimm P.D., Kenny G.M., Sylvester J., Hoak D.C., Cavanagh W., Landin K. Brachytherapy for clinically localized prostate cancer Results at 7 and 8 year follow-up . Sem Surg Onc. 13:1997;438-443.
8. Willins J., Wallner K. CT based dosimetry for transperineal I-125 prostate brachytherapy. Int J Radiat Oncol Biol Phys. 39:1997;347-353.
9. Wallner K., Roy J., Harrison L. Dosimetry guidelines to minimize urethral and rectal morbidity following transperineal I-125 prostate brachytherapy. Int J Radiat Oncol Biol Phys. 32:1995;465-471.
10. Willins J., Wallner K. Time-dependent changes in CT-based dosimetry of I-125 prostate brachytherapy. Rad Onc Invest. 6:1998;157-160.
11. Merrick G.S., Butler W.M., Dorsey A.T., Walbert H.L. Prostatic conformal brachytherapy I-125/Pd-103 postoperative dosimetric analysis . Rad Onc Invest. 5:1997;305-313.
12. Merrick G.S., Butler W.M., Dorsey A.T., Walbert H.L. Influence of timing on the dosimetric analysis of transperineal ultrasound-guided prostatic conformal brachytherapy. Rad Onc Invest. 6:1998;182-190.
13. Merrick GS, Butler WM, Dorsey AT, Lief JH. The potential role of various dosimetric quality indications in prostate brachytherapy. Int J Radiat Oncol Biol Phys 1999;44:717-724.
14. Prestidge B.R., Bice W.S., Prete J.J., Buchholz T.A. A dose volume analysis of permanent transperineal prostatic brachytherapy. Int J Radiat Oncol Biol Phys. 39:1997;238.
15. Prestidge B.R., Bice W.S., Kiefer E.T., Prete J.J. Timing of computed tomography based post-implant assessment following permanent transperineal prostate brachytherapy. Int J Radiat Oncol Biol Phys. 40:1998;1111-1115.
16. Moerland M.A., Wijrdeman H.K., Beersma R., Bakker C.J.G., Battermann J.J. Evaluation of permanent I-125 prostate implants using radiography and magnetic imaging. Int J Radiat Oncol Biol Phys. 37:1997;927-933.
17. Waterman F.M., Yue N., Corn B.W., Dicker A.P. Edema associated with I-125 or Pd-103 prostate brachytherapy and its impact on post-implant dosimetry An analysis based on serial CT acquisitions . Int J Radiat Oncol Biol Phys. 41:1998;1069-1077.
18. Stock R.G., Stone N.N., DeWyngaert J.K., Lavaginini P., Unger P.D. Prostate antigen findings and biopsy results following interactive ultrasound guided transperineal brachytherapy for early stage carcinoma. Cancer. 77:1996;2386-2392.
19. Stock R.G., Stone N.N., Tabert A., Iannuzzi C., DeWyngaert J.K. A dose response study for I-125 prostate implants. Int J Radiat Oncol Biol Phys. 41:1998;101-108.
20. Wallner K., Blasko J., Dattoli M.J. Implant evaluation. Wallner K., Blasko J., Dattoli M.J. Prostate brachytherapy made complicated. 1997;9.1-9.20 Smart Medicine Press, Seattle.
21. Grimm PD. Personal communication.
22. Merrick G.S., Butler W.M., Farthing W.H., Dorsey A.T., Adamovich E. The impact of Gleason score accuracy as a criterion for prostate brachytherapy patient selection. J Brachyther Int. 14:1998;113-121.
23. Nath R., Anderson L.L., Luxton G., Weaver K.A., Williamson J.F., Meigooni A.S. Dosimetry of interstitial brachytherapy sources: Recommendations of the AAPM Radiation Therapy Committee Task Group No. 43. Med Phys. 22:1995;209-234.
24. Merrick GS, Butler WM, Dorsey AT, Lief JH, Walbert HL, Blatt HJ. Rectal dosimetric analysis following prostate brachytherapy. Int J Radiat Oncol Biol Phys 1999;43:1021-1027.
25. Partin A.W., Kattan M.W., Subong E.N.P., Walsh P.C., Wojno K.J., Oesterling J.E., Scardino P.T., Pearson J.D. Combination of prostate-specific antigen, clinical stage and Gleason score to predict pathological stage of localized prostate cancer. JAMA. 277:1997;1445-1451.
26. Cookson M.S., Fleshner N.E., Soloway S.M., Fair W.R. Prognostic significance of prostate-specific antigen in stage T1c prostate cancer treated by radical prostatectomy. Urol. 49:1997;887-893.
27. Wills M.L., Sauvageot J., Partin A.W., Gurganus R., Epstein J.I. Ability of sextant biopsies to predict radical prostatectomy stage. Urol. 51:1998;759-764.
28. Wallner K., Blasko J.C., Dattoli M.J. Implant design. Wallner K., Blasko J., Dattoli M.J. Prostate brachytherapy made complicated. 1997;6.1-6.42 Smart Medicine Press, Seattle.
29. Roy J.N., Wallner K.E., Harrington P.J., Ling C.C., Anderson L.L. A CT-based evaluation method for permanent implants application to prostate . Int J Radiat Oncol Biol Phys. 26:1993;163-169.
30. 125I prostate implants. Int J Radiat Oncol Biol Phys. 34:1996;717-725.
31. Nag S. ABS Prostate brachytherapy consensus statement. American Brachytherapy Society Annual Meeting, Albuquerque, New Mexico, May 31, 1998.
32. Bice W.S., Prestidge B.R., Grimm P.D., Friedland J.L., Feygelman V., Roach M., Prete J.J., Dubois D.F., Blasko J.C. Centralized multiinstitutional postimplant analysis for interstitial prostate brachytherapy. Int J Radiat Oncol Biol Phys. 41:1998;921-927.
33. Waterman F. Personal communication.